ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-PTK7/Exatecan Antibody-drug Conjugate LY4175408

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Eli Lilly.

Furthest: phase 1, since Jun 24, 20251 company-led study, 1 open or runningNext primary completion: Jul 2030 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly11 open or runningphase 1since Jun 24, 2025Jun 24, 2025Jul 2030phase 1 · NCT07046923

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 24, 2025First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT07046923 · 240 enrolled · United States, France, Japan and more

Ahead

  1. Jul 2030Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07046923

TargetBeta

PTK7 →read by rule
“An antibody-drug conjugate (ADC) composed of a fully human Fc-silenced immunoglobulin G1 (IgG1) monoclonal antibody directed against human inactive tyrosine-protein kinase 7 (protein tyrosine kinase 7; PTK7) ”NCIt, by rule

Other programs on PTK7

ProgramCompanyFurthest phaseStudies
Anti-PTK7 Antibody-drug Conjugate SKB518ruleSichuan Kelun Pharmaceuticalphase 23
Anti-PTK7/Exatecan Antibody-drug Conjugate DAY301ruleday-one-biopharmaceuticals-incphase 11
Anti-PTK7 Antibody-drug Conjugate HWK-007rulewhitehawk-therapeutics-incphase 11
Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034ruleideaya-biosciencesphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07046923Carcinoma, Non-Small-Cell Lung · United States, France, Japan and more1Active, not recruitingJul 2030240

How it is read

Names in the registry

  • “LY4175408”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.